Article Text

other Versions

PDF
Original article
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis
  1. Rui Providencia1,
  2. Perry Elliott1,2,
  3. Kiran Patel2,
  4. Jack McCready3,
  5. Girish Babu1,
  6. Neil Srinivasan1,2,
  7. Kostantinos Bronis1,
  8. Nikolaos Papageorgiou1,2,
  9. Anthony Chow1,
  10. Edward Rowland1,
  11. Martin Lowe1,
  12. Oliver R Segal1,
  13. Pier D Lambiase1,2
  1. 1Barts Heart Centre, Barts Health NHS Trust, London, UK
  2. 2Institute of Cardiovascular Science, University College of London, London, United Kingdom
  3. 3Cardiology Department, Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
  1. Correspondence to Dr Pier D Lambiase, Professor of Cardiology, Institute of Cardiovascular Science, University College of London, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK; pierlambiase{at}hotmail.com

Abstract

Objective Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of stroke. The efficacy and safety of catheter ablation in this setting is poorly characterised. We aimed to systematically review the existing literature and to perform a meta-analysis to determine the efficacy and safety of catheter ablation of AF in patients with HCM.

Methods Random-effects meta-analysis of studies comparing HCM versus non-HCM controls. The outcomes of freedom from AF/atrial tachycardia, and acute procedure-related complications were assessed. Studies were searched on MEDLINE, EMBASE, COCHRANE and clinicaltrials.gov.

Results Fourteen studies were considered eligible for the systematic review, of which five were included in the meta-analysis. Freedom from AF/atrial tachycardia relapse was higher in patients without HCM (after a single procedure: 38.7% HCM vs 49.8% controls, OR=2.25, 95% CI 1.09 to 4.64, p=0.03; after ≥1 procedure: 51.8% HCM vs 71.2% controls, OR=2.62, 95% CI 1.52 to 4.51, p=0.0006; I2=33% and 26%, respectively). Risk of procedure-related adverse events was low. Repeat procedures (mean difference=0.16, 95% CI 0.0 to 0.32, p=0.05, I2=53%) and antiarrhythmic drugs (OR=4.70, 95% CI 2.31 to 9.55, p<0.0001, I2=0%) are more frequently needed in patients with HCM to prevent arrhythmia relapse. Sensitivity analyses suggested that the outcome in patients with HCM with less dilated atria and paroxysmal AF may be more comparable to the general population.

Conclusions The observed complication rate of catheter ablation of AF in patients with HCM was low. Even though the risk of relapse is twofold higher, catheter ablation can be effective in patients with HCM and AF, particularly in patients with paroxysmal AF and smaller atria.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles